ArmeniaTuberculosis profile
Population  2015 3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.092 (0.077–0.11) 3 (2.6–3.6)
Mortality (HIV+TB only) 0.014 (<0.01–0.074) 0.46 (0–2.4)
Incidence  (includes HIV+TB) 1.2 (1.1–1.4) 41 (36–46)
Incidence (HIV+TB only) 0.11 (0.099–0.13) 3.7 (3.3–4.2)
Incidence (MDR/RR-TB)** 0.27 (0.2–0.34) 8.9 (6.6–11)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.054 (0.034–0.074) 0.27 (0.14–0.4) 0.32 (0.17–0.48)
Males 0.054 (0.038–0.07) 0.85 (0.67–1) 0.91 (0.71–1.1)
Total 0.11 (0.084–0.13) 1.1 (1–1.2) 1.2 (1.1–1.4)
TB case notifications, 2015  
Total cases notified 1 104
Total new and relapse 1 090
          - % tested with rapid diagnostics at time of diagnosis 18%
          - % with known HIV status 100%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 45%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 89% (79–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.05–0.13)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 99 9%
          - on antiretroviral therapy 99 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  150
(130–180)
Estimated % of TB cases with MDR/RR-TB 11% (8–14) 47% (41–53)  
% notified tested for rifampicin resistance 0% 0% 436
MDR/RR-TB cases tested for resistance to second-line drugs   101
Laboratory-confirmed cases MDR/RR-TB: 101, XDR-TB: 8
Patients started on treatment **** MDR/RR-TB: 268, XDR-TB: 8
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 78% 1 228
Previously treated cases, excluding relapse, registered in 2014 50% 14
HIV-positive TB cases, all types, registered in 2014 60% 77
MDR/RR-TB cases started on second-line treatment in 2013 43% 104
XDR-TB cases started on second-line treatment in 2013 20% 10
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 14%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 5.7
Funding source: 55% domestic, 45% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data